High Versus Low Bicarbonate Bath in Critically-ill Patients Receiving Continuous Renal Replacement Therapy

Acute Kidney Injury Clinical Trial

Official title:

High Versus Low Bicarbonate Bath in Critically-ill Patients Receiving Continuous Renal Replacement Therapy: a Pragmatic Randomized Control Trial

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT03846258
• Other study ID #: 18-010147
• Status: Withdrawn
• Phase: Phase 4
• Start date: May 1, 2019
• Est. completion date: April 1, 2024

Study information

• Verified date: April 2021
• Source: Mayo Clinic
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Researchers are trying to determine which dialysis solution, low bicarbonate fluid (22 mmol/L) or high bicarbonate fluid (32 mmol/L), is better in subjects with acute kidney injury (acute kidney failure) and metabolic acidosis that are admitted to the intensive care unit and require continuous renal replacement therapy (also known as continuous dialysis).

Description:

This is a prospective randomized trial that will be conducted at Mayo Clinic in Rochester Minnesota. It will be based on Good Clinical Practice Standards and performed under IRB supervision. This will be a pragmatic clinical trial due to the nature of the intervention and short interval for making a clinical decision. While dialysis in general is valid in cases of severe AKI and metabolic acidosis, there remains uncertainty as to which replacement fluid to use. In one retrospective study, using high bicarbonate replacement fluid was associated with worse outcomes, even after accounting for several important confounders. While this intervention is valid in cases of severe metabolic acidosis (pH<7), there has not been much data to support the use of either intervention in cases of any metabolic acidosis in general.

While both interventions are equally valid, to our knowledge, there is no randomized clinical trial evaluating the difference of either intervention on outcomes. There is limited evidence in the literature on benefit or harm associated with either of the interventions on the outcomes thus generating a clinical equipoise. This pivotal study should help guide nephrologists and intensivists on the appropriate prescription of CRRT.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: April 1, 2024
• Est. primary completion date: April 1, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 100 Years

Eligibility

Inclusion Criteria

• Adult patients (= 18 years of age)

• Ability to obtain informed consent, either from patient or legally authorized representative (LAR)

• Diagnosis of AKI according to KDIGO definition [an increase in serum creatinine concentration of greater than or equal to 0.3 mg/dL within the first 48 hours of injury, a relative increase in serum creatinine of greater than or equal to 50% (1.5-fold from baseline) within the first 7 days of injury, or a reduction in urine output (<0.5 mL/kg/h for more than 6 hours)]

• CRRT initiated for the first time during current ICU admission.

• Bicarbonate = 22 mEq/L

• Arterial pH between 7.05 and 7.25(if an ABG is not available, venous pH must be between 7.00 and 7.20)

Exclusion Criteria

• Pregnancy (women of child-bearing potential must have a negative pregnancy test)

• Diagnosis of End-Stage renal disease and receiving Hemodialysis or peritoneal dialysis prior to ICU admission (this information will be easily obtained by the nephrology team)

• Arterial pH <7.05 or >7.25 (if an ABG is not available, Venous pH <7.00 or >7.20)

• Potassium level >6.0 mmol/L

• Severe acute liver failure meeting all the following criteria):

• INR >2

• AST/ALT more than 500 U/L and

• Bilirubin more than 12 mg/dL)

• Previous enrollment in this study

Related Conditions & MeSH terms

• Acidosis
• Acute Kidney Failure
• Acute Kidney Injury
• Metabolic Acidosis
• Renal Insufficiency

Intervention

Drug:
• Low bicarbonate solution (22 mmol/L)
Participants randomized to this arm will be started on CRRT using Phoxillum as the replacement fluid.
• High Bicarbonate solution (32 mmol/L)
Participants randomized to this arm will be started on CRRT using Prismasate as the replacement fluid.

Locations

Country	Name	City	State
United States	Mayo Clinic in Rochester	Rochester	Minnesota

Sponsors (1)

Lead Sponsor	Collaborator
Mayo Clinic

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	In-hospital mortality	Discharge status: death	120 days
Secondary	Time to achieve pH >7.3	The number of hours it took each participant to have an arterial pH of >7.3 or a venous pH > 7.35 following CRRT initiation	30 days
Secondary	Major Adverse Kidney events	Composite outcome of death, persistent kidney dysfunction (creatinine more than 1.5 times baseline) or need for renal replacement therapy at specified time intervals.	120 Days